Breast Cancer and Melanoma
Among the group’s current objectives is putting into practice tumour sequencing in patients with breast cancer. We are studying the efficacy of PI3K/mTOR inhibitors and their relationship with mutational state, as well as continuing research on the factors involved in resistance to HER2 treatments and the strategies aimed at reversing them.
We are also studying how effective PARP inhibitors are in breast cancer and investigating the implementation of therapeutic strategies and differentiated clinical trials for tumour subtypes.
08:30 h a 18:00 h